Cyclopharm
Cyclopharm is a global radiopharmaceutical company focused on lung imaging solutions. Their flagship product, Technegas, is used for pulmonary embolism diagnosis and other lung conditions. The company aims to advance nuclear pulmonology imaging through innovation and a commitment to superior patient care.
Short position
Cyclopharm (ASX:CYC) has 0.00% of its shares on issue reported as short positions as of 28 Sept 2026, or about 343 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.19% in August 2025. CYC is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Cyclopharm (CYC) company profile
Profile, insiders and operations
Company
AI-generated research profile of Cyclopharm
CYC intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links